Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
Date:9/15/2008

was a multi-center, randomized, double blind, placebo controlled, dose-finding study conducted at 84 sites in Western Europe, Eastern Europe and Canada. Subjects (n = 567) were between 60 and 85 years of age and diagnosed with probable Alzheimer's disease that was classified, based on a quantitative scale, as mild or moderate in severity. Subjects were assigned to one of three dose groups of AZD3480, to an active comparator, donepezil, or to placebo and dosed over 12 weeks. The primary outcome measure in the trial was change from baseline after 12 weeks on ADAS-Cog. A number of secondary outcome measures were also used in the trial.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

About Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenia, pain and major depressive disorder, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
2. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
7. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
8. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
9. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Sony Biotechnology Inc. ("Sony") today announced the launch ... 130um sorting chip.  Sony will also be exhibiting its newly ... Cell Sorter, the EC800 flow cytometer, and new SP6800 Spectral ... which will be held at the San Diego ... , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... 2011 ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Citi 2011 Global Healthcare Conference ... conference is being held at the Hilton New York Hotel ... and chief financial officer, of ViroPharma, will present at the ...
... Feb. 28, 2011 Rock Creek Pharmaceuticals, a wholly ... CIGX ) has been notified by the Roskamp Institute ... review board (IRB) approval to conduct a three-month, multi-site ...  The study (referred to as the "Flint Study"), will ...
Cached Medicine Technology:ViroPharma to Participate in Two March Healthcare Conferences 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 3Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 4
(Date:5/19/2013)... (PRWEB) May 19, 2013 According ... Market Analysis and Forecast (2013 – 2018): By ... Defense, Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, ... of image sensor market was $8.00 billion in ... in 2018, at an estimated CAGR of 3.84% ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... 19, 2013 Vegas Hotel Escapes, the ... to announce the launch it's all new vacation packages ... Grand on 5/19/2013. Consumers traveling to Las Vegas will ... available on VegasHotelEscapes.com's website. Travelers will be pleased to ... competitors price. , Vegas Hotel Escapes specializes in helping ...
(Date:5/19/2013)... IL (PRWEB) May 19, 2013 Beginning Wednesday, ... River Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" ... Belvidere. RRVBC will provide hot dogs and all the ... ice-cold slushies each day throughout the summer. “Donors are our ... maintain a stable and adequate blood supply. This is ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... Pressure-Lowering Device to be Available at 1,440 Stores ... April 28 InterCure Ltd., a medical,device company ... (TASE: INCR),today announced that its RESPeRATE(R) hypertension treatment ... into,full-scale retail distribution within the United Kingdom this ...
... motherhood more than doubled in six years among teenage ... published in the May issue of Diabetes Care. ... at gestational diabetes (diabetes that develops during pregnancy, then ... the largest and most diverse study to examine pre-pregnancy ...
... they take, changes in biological clock put many at risk ... Many older adults don,t get enough sleep, which can increase ... disease and diabetes, says the American Academy of Sleep Medicine. ... disturbed sleep and waking up tired every day aren,t a ...
... osteoporosis, , , SATURDAY, April 26 (HealthDay News) -- While ... harmless enough, recent research suggests that those tasty drinks ... enough evidence that high consumption of soda and carbonated ... children, and that,s a real concern and people should ...
... Irvine, Calif., April 25, 2008 -- Advance directives, or ... life-sustaining treatment preferences often change without people being aware ... by UC Irvine researchers Peter Ditto and Elizabeth Loftus. ... in the discrepancy between an individual,s true preferences for ...
... PRINCETON, N.J., April 25 Medarex, Inc.,(Nasdaq: ... BMY ) today announced,that, after meeting with the ... delay the Biologics License Application (BLA) submission for,ipilimumab, ... The FDA has requested additional overall survival (OS),data ...
Cached Medicine News:Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Kaiser Permanente study finds diabetes doubling before motherhood 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 3Health News:Elderly More Likely to Battle Sleep Disorders 2Health News:Cola May Be Bad to the Bones 2Health News:Cola May Be Bad to the Bones 3Health News:Study shows false memories complicate end-of-life treatment decisions 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 3Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 4Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 5
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 900 high frequency desiccator forever removes the need to go through a tedious multi-step process to change from low to high power....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: